Kobashigawa, J <br/><br/>
Daclizumab is associated with decreased rejection and no increased mortality in cardiac transplant patients receiving MMF, cyclosporine, and corticosteroids.  [electronic resource] 

 -  Transplantation proceedings  Mar 2005 
 - 1333-9 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0041-1345 
<br/><br/><label>Standard No.: </label>10.1016/j.transproceed.2004.12.135  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Antibodies, Monoclonal--therapeutic use<br/>Antibodies, Monoclonal, Humanized<br/>Daclizumab<br/>Drug Therapy, Combination<br/>Female<br/>Graft Rejection--epidemiology<br/>Heart Transplantation--immunology<br/>Humans<br/>Immunoglobulin G--therapeutic use<br/>Immunosuppressive Agents--therapeutic use<br/>Incidence<br/>Infections--epidemiology<br/>Male<br/>Middle Aged<br/>Multivariate Analysis<br/>Postoperative Complications--classification<br/>Registries<br/>Survival Analysis<br/>Time Factors<br/>United States